Compare, Analyse VENUS REMEDIES with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs TEVA PHARMA (Israel) - Comparison Results

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 VENUS REMEDIES   TEVA PHARMA
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
TEVA PHARMA
Dec-13
VENUS REMEDIES/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs1263,050-   
Low Rs612,650-   
Sales per share (Unadj.) Rs301.81,750.4-  
Earnings per share (Unadj.) Rs-24.9109.3-  
Cash flow per share (Unadj.) Rs2.5250.8-  
Dividends per share (Unadj.) Rs095.72-  
Dividend yield (eoy) %03.4 0.0%  
Book value per share (Unadj.) Rs293.31,944.4-  
Shares outstanding (eoy) m12.34848.00-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.31.6 19.0%   
Avg P/E ratio x-3.826.1 -14.4%  
P/CF ratio (eoy) x36.711.4 323.4%  
Price / Book Value ratio x0.31.5 21.8%  
Dividend payout %087.5 0.0%   
Avg Mkt Cap Rs m1,1542,416,571 0.0%   
No. of employees `0000.944.9 2.1%   
Total wages/salary Rs m3930-   
Avg. sales/employee Rs Th4,026.133,025.8 12.2%   
Avg. wages/employee Rs Th425.00-   
Avg. net profit/employee Rs Th-331.82,063.1 -16.1%   
INCOME DATA
Net Sales Rs m3,7241,484,344 0.3%  
Other income Rs m230-   
Total revenues Rs m3,7471,484,344 0.3%   
Gross profit Rs m395406,488 0.1%  
Depreciation Rs m338119,981 0.3%   
Interest Rs m35429,155 1.2%   
Profit before tax Rs m-275257,353 -0.1%   
Minority Interest Rs m01,169 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-168,938 0.0%   
Tax Rs m32-3,142 -1.0%   
Profit after tax Rs m-30792,726 -0.3%  
Gross profit margin %10.627.4 38.7%  
Effective tax rate %-11.5-1.2 940.2%   
Net profit margin %-8.26.2 -131.9%  
BALANCE SHEET DATA
Current assets Rs m2,6381,002,520 0.3%   
Current liabilities Rs m2,305874,283 0.3%   
Net working cap to sales %8.98.6 103.5%  
Current ratio x1.11.1 99.8%  
Inventory Days Days13591 149.2%  
Debtors Days Days4696 48.3%  
Net fixed assets Rs m4,871484,819 1.0%   
Share capital Rs m1233,654 3.4%   
"Free" reserves Rs m3,4960-   
Net worth Rs m3,6191,648,825 0.2%   
Long term debt Rs m1,374758,978 0.2%   
Total assets Rs m7,5093,392,202 0.2%  
Interest coverage x0.29.8 2.3%   
Debt to equity ratio x0.40.5 82.5%  
Sales to assets ratio x0.50.4 113.3%   
Return on assets %0.63.6 17.6%  
Return on equity %-8.55.6 -150.8%  
Return on capital %1.64.9 32.1%  
Exports to sales %00-   
Imports to sales %13.90-   
Net fx Rs m-5170-   
CASH FLOW
From Operations Rs m514236,528 0.2%  
From Investments Rs m-123-83,811 0.1%  
From Financial Activity Rs m-387-283,731 0.1%  
Net Cashflow Rs m4-131,015 -0.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 73.07 Rs / USD

Compare VENUS REMEDIES With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  

Compare VENUS REMEDIES With: AJANTA PHARMA  STERLING BIOTECH  NATCO PHARMA  TTK HEALTHCARE  AUROBINDO PHARMA  



Today's Market

Bloodbath on Dalal Street: 6 Reasons Why Sensex Nosedived 1,939 Points Today(Closing)

Indian share markets witnessed a sharp sell-off today and ended deep in the red.

Related Views On News

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps (Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Intraday Trading for a Living (Fast Profits Daily)

Feb 15, 2021

In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.

Top 5 Stocks Mutual Funds Bought and Sold in January 2021 (Sector Info)

Feb 16, 2021

A look at what India's top equity mutual funds bought and sold in January 2021.

I Would Recommend this Small-cap Stock Over Tesla (Profit Hunter)

Feb 16, 2021

Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.

More
-->

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

OUR TOP 5 IDEAS

Access Now: Eight Steps to Your Eight Figure Fortune
Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
Free Report: The Secret to Increasing Your Trading Profits Daily!
No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.

VENUS REMEDIES SHARE PRICE


Feb 26, 2021 03:36 PM

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES - ALEMBIC COMPARISON

COMPARE VENUS REMEDIES WITH

FEATURED VIDEOS

Gold 65,000 and Silver 84,000 in 2022

How Long Before a Big Stock Market Crash

I Believe the Investment of the Year Will Be...

Nasdaq & Nifty Could Reverse

More Featured Videos

MARKET STATS